Short answer
Stoke Therapeutics, Inc. (STOK) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $6M (down 96.1% year over year) with net income of −$50M.
Q1 2026 key financials · XBRL
- Revenue
- $6M
- −96.1% YoY
- Net income
- −$50M
- −144.3% YoY
- Operating margin
- -857.6%
- EPS (diluted)
- −$0.79
- −141.6% YoY
Source: XBRL data from the Stoke Therapeutics, Inc. (STOK) Q1 2026 10-Q on SEC EDGAR. USD.
Stoke Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New STK-002 clinical program risk triggered by first patient dosing in OSPREY Phase 1 study in February 2026
- Zorevunersen advanced to EMPEROR Phase 3 after first patient dosing in August 2025, increasing late-stage execution risk
- FDA approval uncertainty heightened by post-Chevron legal challenges to agency regulations
- Rare diseases risk: Dravet syndrome incidence approximately one in 15,600 births and ADOA one in 30,000 births
- Funding risk: continued operating losses and expected additional financing needs before potential product profitability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Stoke Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.